Neumora Historical Balance Sheet

NMRA Stock

1.14 0.06 5.00%

Trend analysis of Neumora Therapeutics, balance sheet accounts such as Property Plant And Equipment Net of 5.2 M provides information on Neumora Therapeutics,'s total assets, liabilities, and equity, which is the actual value of Neumora Therapeutics, to its prevalent stockholders. By breaking down trends over time using Neumora Therapeutics, balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Neumora Therapeutics, latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Neumora Therapeutics, is a good buy for the upcoming year.

Neumora Therapeutics, Inventory

70,000

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neumora Therapeutics,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For information on how to trade Neumora Stock refer to our How to Trade Neumora Stock guide.

About Neumora Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Neumora Therapeutics, at a specified time, usually calculated after every quarter, six months, or one year. Neumora Therapeutics, Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Neumora Therapeutics, and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Neumora currently owns. An asset can also be divided into two categories, current and non-current.

Neumora Therapeutics, Balance Sheet Chart

At present, Neumora Therapeutics,'s Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Stockholder Equity is expected to grow to about 301.4 M, whereas Total Current Liabilities is forecasted to decline to about 20.4 M.

Total Current Liabilities Common Stock Shares Outstanding Total Liab Short Long Term Debt Total

Total Current Liabilities

Total Current Liabilities is an item on Neumora Therapeutics, balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Neumora Therapeutics, are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Most accounts from Neumora Therapeutics,'s balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Neumora Therapeutics, current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neumora Therapeutics,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For information on how to trade Neumora Stock refer to our How to Trade Neumora Stock guide.At present, Neumora Therapeutics,'s Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Stockholder Equity is expected to grow to about 301.4 M, whereas Total Current Liabilities is forecasted to decline to about 20.4 M.

	2022	2023	2024	2025 (projected)
Other Current Liabilities	13.2M	21.4M	24.7M	18.9M
Short and Long Term Debt Total	8.4M	5.2M	1.9M	1.8M

Other Current Liab Short Long Term Debt Total

Neumora Therapeutics, balance sheet Correlations

	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Retained Earnings	Common Stock Shares Outstanding	Total Liab	Net Invested Capital	Net Working Capital	Short Long Term Debt Total	Other Current Liab	Current Deferred Revenue	Net Debt	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Other Current Assets	Other Stockholder Equity	Short Term Debt	Common Stock	Property Plant Equipment	Other Liab	Inventory	Deferred Long Term Liab	Non Current Liabilities Other
Total Current Liabilities		0.16	-0.98	-0.92	0.58	0.54	0.16	0.96	0.47	0.95	0.94	-0.42	0.58	0.86	0.9	0.87	0.78	0.5	0.8	0.9	0.84	0.85	-0.85	0.85	-0.47
Total Stockholder Equity	0.16		-0.16	-0.45	0.65	-0.72	1.0	0.1	-0.28	0.34	0.37	0.16	-0.5	-0.06	0.16	0.34	0.31	0.89	0.21	0.38	0.32	0.38	-0.36	0.38	-0.86
Net Tangible Assets	-0.98	-0.16		0.92	-0.62	-0.54	-0.16	-0.97	-0.58	-0.92	-0.9	0.43	-0.55	-0.84	-0.94	-0.89	-0.86	-0.47	-0.89	-0.9	-0.86	-0.87	0.9	-0.87	0.43
Retained Earnings	-0.92	-0.45	0.92		-0.83	-0.23	-0.45	-0.84	-0.31	-0.93	-0.91	0.16	-0.3	-0.73	-0.83	-0.89	-0.75	-0.73	-0.78	-0.97	-0.85	-0.91	0.91	-0.91	0.72
Common Stock Shares Outstanding	0.58	0.65	-0.62	-0.83		-0.15	0.65	0.53	-0.02	0.67	0.62	0.11	-0.02	0.46	0.58	0.58	0.54	0.84	0.54	0.72	0.51	0.62	-0.64	0.63	-0.84
Total Liab	0.54	-0.72	-0.54	-0.23	-0.15		-0.72	0.62	0.62	0.34	0.31	-0.53	0.84	0.64	0.54	0.28	0.35	-0.42	0.41	0.24	0.27	0.23	-0.26	0.22	0.43
Net Invested Capital	0.16	1.0	-0.16	-0.45	0.65	-0.72		0.1	-0.28	0.34	0.37	0.16	-0.5	-0.06	0.16	0.34	0.31	0.89	0.21	0.38	0.32	0.38	-0.36	0.38	-0.86
Net Working Capital	0.96	0.1	-0.97	-0.84	0.53	0.62	0.1		0.55	0.88	0.87	-0.59	0.64	0.87	0.96	0.78	0.85	0.42	0.83	0.77	0.75	0.74	-0.78	0.74	-0.36
Short Long Term Debt Total	0.47	-0.28	-0.58	-0.31	-0.02	0.62	-0.28	0.55		0.26	0.26	-0.35	0.29	0.27	0.54	0.61	0.72	-0.27	0.8	0.39	0.62	0.54	-0.62	0.54	0.35
Other Current Liab	0.95	0.34	-0.92	-0.93	0.67	0.34	0.34	0.88	0.26		0.99	-0.43	0.55	0.88	0.89	0.82	0.72	0.68	0.7	0.89	0.78	0.81	-0.8	0.81	-0.65
Current Deferred Revenue	0.94	0.37	-0.9	-0.91	0.62	0.31	0.37	0.87	0.26	0.99		-0.45	0.52	0.85	0.87	0.82	0.71	0.68	0.68	0.88	0.8	0.81	-0.79	0.81	-0.65
Net Debt	-0.42	0.16	0.43	0.16	0.11	-0.53	0.16	-0.59	-0.35	-0.43	-0.45		-0.74	-0.62	-0.64	-0.15	-0.52	0.01	-0.34	-0.06	-0.14	-0.07	0.12	-0.06	-0.11
Non Currrent Assets Other	0.58	-0.5	-0.55	-0.3	-0.02	0.84	-0.5	0.64	0.29	0.55	0.52	-0.74		0.86	0.65	0.2	0.32	-0.13	0.28	0.25	0.18	0.15	-0.17	0.15	0.14
Other Assets	0.86	-0.06	-0.84	-0.73	0.46	0.64	-0.06	0.87	0.27	0.88	0.85	-0.62	0.86		0.89	0.56	0.59	0.36	0.56	0.66	0.52	0.54	-0.55	0.54	-0.34
Cash And Short Term Investments	0.9	0.16	-0.94	-0.83	0.58	0.54	0.16	0.96	0.54	0.89	0.87	-0.64	0.65	0.89		0.75	0.89	0.45	0.85	0.75	0.71	0.71	-0.76	0.71	-0.39
Net Receivables	0.87	0.34	-0.89	-0.89	0.58	0.28	0.34	0.78	0.61	0.82	0.82	-0.15	0.2	0.56	0.75		0.82	0.51	0.9	0.95	1.0	0.99	-0.99	0.99	-0.47
Other Current Assets	0.78	0.31	-0.86	-0.75	0.54	0.35	0.31	0.85	0.72	0.72	0.71	-0.52	0.32	0.59	0.89	0.82		0.43	0.96	0.71	0.79	0.77	-0.84	0.77	-0.32
Other Stockholder Equity	0.5	0.89	-0.47	-0.73	0.84	-0.42	0.89	0.42	-0.27	0.68	0.68	0.01	-0.13	0.36	0.45	0.51	0.43		0.34	0.64	0.47	0.55	-0.52	0.55	-0.99
Short Term Debt	0.8	0.21	-0.89	-0.78	0.54	0.41	0.21	0.83	0.8	0.7	0.68	-0.34	0.28	0.56	0.85	0.9	0.96	0.34		0.79	0.87	0.86	-0.92	0.86	-0.26
Common Stock	0.9	0.38	-0.9	-0.97	0.72	0.24	0.38	0.77	0.39	0.89	0.88	-0.06	0.25	0.66	0.75	0.95	0.71	0.64	0.79		0.93	0.97	-0.95	0.97	-0.64
Property Plant Equipment	0.84	0.32	-0.86	-0.85	0.51	0.27	0.32	0.75	0.62	0.78	0.8	-0.14	0.18	0.52	0.71	1.0	0.79	0.47	0.87	0.93		0.99	-0.98	0.99	-0.43
Other Liab	0.85	0.38	-0.87	-0.91	0.62	0.23	0.38	0.74	0.54	0.81	0.81	-0.07	0.15	0.54	0.71	0.99	0.77	0.55	0.86	0.97	0.99		-0.99	1.0	-0.53
Inventory	-0.85	-0.36	0.9	0.91	-0.64	-0.26	-0.36	-0.78	-0.62	-0.8	-0.79	0.12	-0.17	-0.55	-0.76	-0.99	-0.84	-0.52	-0.92	-0.95	-0.98	-0.99		-0.99	0.48
Deferred Long Term Liab	0.85	0.38	-0.87	-0.91	0.63	0.22	0.38	0.74	0.54	0.81	0.81	-0.06	0.15	0.54	0.71	0.99	0.77	0.55	0.86	0.97	0.99	1.0	-0.99		-0.53
Non Current Liabilities Other	-0.47	-0.86	0.43	0.72	-0.84	0.43	-0.86	-0.36	0.35	-0.65	-0.65	-0.11	0.14	-0.34	-0.39	-0.47	-0.32	-0.99	-0.26	-0.64	-0.43	-0.53	0.48	-0.53

Click cells to compare fundamentals

Neumora Therapeutics, Account Relationship Matchups

Neumora Therapeutics, balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	197.9M	429.3M	426.2M	496.2M	317.0M	342.2M
Total Current Liabilities	9.4M	23.3M	23.7M	25.1M	29.9M	20.4M
Total Stockholder Equity	(94.4M)	(325.2M)	(446.9M)	469.1M	287.1M	301.4M
Property Plant And Equipment Net	3.9M	4.0M	10.6M	6.9M	2.9M	5.2M
Retained Earnings	(99.3M)	(336.6M)	(467.5M)	(703.4M)	(947.2M)	(899.9M)
Accounts Payable	2.4M	1.6M	7.1M	337K	3.3M	2.7M
Cash	192.0M	409.2M	240.9M	374.0M	142.1M	249.0M
Non Current Assets Total	4.1M	13.7M	38.3M	17.9M	2.9M	2.8M
Non Current Liabilities Total	283.0M	731.2M	849.4M	2.0M	22K	20.9K
Capital Lease Obligations	2.0M	2.1M	8.4M	5.2M	1.9M	3.6M
Total Liab	292.3M	754.5M	873.1M	27.1M	29.9M	28.4M
Net Invested Capital	(94.4M)	(325.2M)	(446.9M)	469.1M	287.1M	301.4M
Property Plant And Equipment Gross	4.0M	4.6M	11.7M	8.3M	5.0M	6.2M
Total Current Assets	193.8M	415.6M	388.0M	478.3M	314.1M	328.1M
Net Working Capital	184.5M	392.3M	364.3M	453.2M	284.2M	307.7M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

When determining whether Neumora Therapeutics, offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Neumora Therapeutics,'s financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Neumora Therapeutics, Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Neumora Therapeutics, Stock:

How To Invest In Neumora

Details

Is Neumora Stock a good investment?

Details

What is Neumora Therapeutics,'s Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For information on how to trade Neumora Stock refer to our How to Trade Neumora Stock guide.

You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neumora Therapeutics,. If investors know Neumora will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neumora Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.53)

Return On Assets

(0.41)

Return On Equity

(0.64)

The market value of Neumora Therapeutics, is measured differently than its book value, which is the value of Neumora that is recorded on the company's balance sheet. Investors also form their own opinion of Neumora Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Neumora Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neumora Therapeutics,'s market value can be influenced by many factors that don't directly affect Neumora Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Neumora Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Neumora Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neumora Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Neumora Historical Balance Sheet

Neumora Therapeutics, Inventory

70,000

About Neumora Balance Sheet Analysis

Neumora Therapeutics, Balance Sheet Chart

Total Current Liabilities

Common Stock Shares Outstanding

Total Liab

Neumora Therapeutics, balance sheet Correlations

Neumora Therapeutics, Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Neumora Therapeutics, balance sheet Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Net Invested Capital	+ 1.0	Total Stockholder Equity
Property Plant Equipment	+ 1.0	Net Receivables
Deferred Long Term Liab	+ 1.0	Other Liab
Current Deferred Revenue	+ 0.99	Other Current Liab
Other Liab	+ 0.99	Net Receivables
Deferred Long Term Liab	+ 0.99	Net Receivables

Deferred Long Term Liab	- 0.99	Inventory
Inventory	- 0.99	Other Liab
Non Current Liabilities Other	- 0.99	Other Stockholder Equity
Inventory	- 0.99	Net Receivables
Inventory	- 0.98	Property Plant Equipment
Net Tangible Assets	- 0.98	Total Current Liabilities